All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2020-D-1079
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research; Draft Guidance for Industry; Availability
Documents
4
Comments
65
Key Dates
Comment Period OpensJul 22, 2020
Comment Period ClosesSep 22, 2020
Documents
| Type | Title | Status |
|---|---|---|
Notice |
Comment Statistics
Total Comments
65
Keywords
2019-965
CDER
Guidance for Industry
Cannabis and Cannabis-Derived
Compounds
Quality Considerations for Clinical Research
OPEN
Data from Regulations.gov